CymaBay Therapeutics
As of March 22, 2024, we are joining Gilead
to advance our shared mission in developing therapies for people living with challenging liver diseases. Learn more by visiting www.gilead.com.
to advance our shared mission in developing therapies for people living with challenging liver diseases. Learn more by visiting www.gilead.com.
Our company focus is to support the scientific, healthcare, and advocacy communities dedicated to improving the standard of care for our patients.
Our highly committed employees play a critical role in CymaBay’s success. We live our core values of innovation, teamwork, accountability, integrity, and respect in everything we do. We seek like-minded individuals dedicated to developing their careers by joining our innovative, fast-growing company.
Our unique medicines show promise in targeting the underlying causes of liver, metabolic and other inflammatory diseases while reducing symptoms and slowing progression. Supported by an extensive development program, our lead compound, seladelpar, is the first delpar to be developed for the treatment of PBC.